Literature DB >> 20850578

Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.

Jochen G Schneider1, Sarah R Amend, Katherine N Weilbaecher.   

Abstract

Integrins on both tumor cells and the supporting host stromal cells in bone (osteoclasts, new blood vessels, inflammatory cells, platelets and bone marrow stromal cells) play key roles in enhancing bone metastasis. Tumor cells localize to specific tissues through integrin-mediated contacts with extracellular matrix and stromal cells. Integrin expression and signaling are perturbed in cancer cells, allowing them to "escape" from cell-cell and cell-matrix tethers, invade, migrate and colonize within new tissues and matrices. Integrin signaling through αvβ3 and VLA-4 on tumor cells can promote tumor metastasis to and proliferation in the bone microenvironment. Osteoclast (OC) mediated bone resorption is a critical component of bone metastasis and can promote tumor growth in bone and αvβ3 integrins are critical to OC function and development. Tumors in the bone microenvironment can recruit new blood vessel formation, platelets, pro-tumor immune cells and bone marrow stromal cells that promote tumor growth and invasion in bone. Integrins and their ligands play critical roles in platelet aggregation (αvβ3 and αIIbβ3), hematopoietic cell mobilization (VLA-4 and osteopontin), neoangiogenesis (αvβ3, αvβ5, α6β4, and β1 integrin) and stromal function (osteopontin and VLA-4). Integrins are involved in the pathogenesis of bone metastasis at many levels and further study to define integrin dysregulation by cancer will yield new therapeutic targets for the prevention and treatment of bone metastasis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20850578      PMCID: PMC3010439          DOI: 10.1016/j.bone.2010.09.016

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  284 in total

1.  Pathology and therapeutics, in fifty lectures. 1871.

Authors:  Theodor Billroth
Journal:  Clin Orthop Relat Res       Date:  2003-03       Impact factor: 4.176

Review 2.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

3.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Authors:  Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher
Journal:  Lancet Oncol       Date:  2010-03-31       Impact factor: 41.316

4.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

5.  Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Authors:  Penelope D Ottewell; Hannu Mönkkönen; Mark Jones; Diane V Lefley; Robert E Coleman; Ingunn Holen
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

6.  Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro.

Authors:  Azza Gramoun; Seema Shorey; Jill D Bashutski; S Jeffrey Dixon; Stephen M Sims; Johan N M Heersche; Morris F Manolson
Journal:  J Cell Biochem       Date:  2007-10-01       Impact factor: 4.429

7.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

8.  Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.

Authors:  Jeffrey A Nemeth; Michael L Cher; Zhao Zhou; Chadwick Mullins; Sunita Bhagat; Mohit Trikha
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

9.  Integrin beta4 signaling promotes tumor angiogenesis.

Authors:  Sotiris N Nikolopoulos; Pamela Blaikie; Toshiaki Yoshioka; Wenjun Guo; Filippo G Giancotti
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

10.  Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis.

Authors:  Li Yang; Claire M Edwards; Gregory R Mundy
Journal:  J Bone Miner Res       Date:  2010-08       Impact factor: 6.741

View more
  62 in total

1.  Enterolobium contortisiliquum trypsin inhibitor (EcTI), a plant proteinase inhibitor, decreases in vitro cell adhesion and invasion by inhibition of Src protein-focal adhesion kinase (FAK) signaling pathways.

Authors:  Cláudia Alessandra Andrade de Paula; Vivien Jane Coulson-Thomas; Joana Gasperazzo Ferreira; Paloma Korehisa Maza; Erika Suzuki; Adriana Miti Nakahata; Helena Bonciani Nader; Misako Uemura Sampaio; Maria Luiza V Oliva
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

Review 2.  Bone metastasis and the metastatic niche.

Authors:  Guangwen Ren; Mark Esposito; Yibin Kang
Journal:  J Mol Med (Berl)       Date:  2015-08-15       Impact factor: 4.599

3.  Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases.

Authors:  Leandro Marcelo Martinez; Valeria Beatriz Fernández Vallone; Vivian Labovsky; Hosoon Choi; Erica Leonor Hofer; Leonardo Feldman; Raúl Horacio Bordenave; Emilio Batagelj; Federico Dimase; Ana Rodriguez Villafañe; Norma Alejandra Chasseing
Journal:  Clin Exp Metastasis       Date:  2013-10-31       Impact factor: 5.150

Review 4.  Molecular alterations that drive breast cancer metastasis to bone.

Authors:  Penelope D Ottewell; Liam O'Donnell; Ingunn Holen
Journal:  Bonekey Rep       Date:  2015-03-18

5.  Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer.

Authors:  Na Li; Jian-ping Zhang; Shan Guo; Jie Min; Li-li Liu; Hai-chuan Su; Ying-ming Feng; He-long Zhang
Journal:  Mol Biol Rep       Date:  2011-06-16       Impact factor: 2.316

Review 6.  Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.

Authors:  Ami Patel; Harika Sabbineni; Andrea Clarke; Payaningal R Somanath
Journal:  Life Sci       Date:  2016-05-28       Impact factor: 5.037

7.  The TMEFF2 tumor suppressor modulates integrin expression, RhoA activation and migration of prostate cancer cells.

Authors:  Xiaofei Chen; Joshua M Corbin; Greg J Tipton; Li V Yang; Adam S Asch; Maria J Ruiz-Echevarría
Journal:  Biochim Biophys Acta       Date:  2014-03-13

8.  Three-Dimensional Mechanical Loading Modulates the Osteogenic Response of Mesenchymal Stem Cells to Tumor-Derived Soluble Signals.

Authors:  Maureen E Lynch; Aaron E Chiou; Min Joon Lee; Stephen C Marcott; Praveen V Polamraju; Yeonkyung Lee; Claudia Fischbach
Journal:  Tissue Eng Part A       Date:  2016-08-01       Impact factor: 3.845

9.  Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.

Authors:  Michael H Ross; Alison K Esser; Gregory C Fox; Anne H Schmieder; Xiaoxia Yang; Grace Hu; Dipanjan Pan; Xinming Su; Yalin Xu; Deborah V Novack; Thomas Walsh; Graham A Colditz; Gabriel H Lukaszewicz; Elizabeth Cordell; Joshua Novack; James A J Fitzpatrick; David L Waning; Khalid S Mohammad; Theresa A Guise; Gregory M Lanza; Katherine N Weilbaecher
Journal:  Cancer Res       Date:  2017-08-30       Impact factor: 12.701

Review 10.  Targeting bone physiology for the treatment of metastatic prostate cancer.

Authors:  Karen A Autio; Michael J Morris
Journal:  Clin Adv Hematol Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.